Y-mAbs Therapeutics Stock Forecast, Price & News

Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

Is Y-mAbs Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics or view top-rated stocks.

How has Y-mAbs Therapeutics' stock price been impacted by COVID-19?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, YMAB stock has decreased by 55.5% and is now trading at $10.22.
View which stocks have been most impacted by COVID-19.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Y-mAbs Therapeutics.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its earnings results on Thursday, November, 4th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.08. The business earned $8.97 million during the quarter, compared to the consensus estimate of $10.87 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 19.08% and a negative net margin of 83.21%. During the same quarter last year, the company earned ($0.82) EPS.
View Y-mAbs Therapeutics' earnings history.

What price target have analysts set for YMAB?

5 brokers have issued 1 year price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $25.00 to $68.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 320.7% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:

• Thomas Gad, Chairman, President & Head-Business Development
• Claus Juan Møller-San Pedro, Director, Chief Executive & Commercial Officer
• Joris Wiel Jan Wilms, Chief Operating Officer & Senior Vice President
• Bo Kruse, CFO, Secretary. Treasurer & Executive VP (LinkedIn Profile)
• Torben Lund-Hansen, Chief Technology Officer & Senior Vice President

Who are some of Y-mAbs Therapeutics' key competitors?

Some companies that are related to Y-mAbs Therapeutics include Turning Point Therapeutics (TPTX), ChemoCentryx (CCXI), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Prothena (PRTA), Agios Pharmaceuticals (AGIO), Supernus Pharmaceuticals (SUPN), Verve Therapeutics (VERV), Travere Therapeutics (TVTX), Dynavax Technologies (DVAX), BridgeBio Pharma (BBIO), Morphic (MORF), Zogenix (ZGNX), Cassava Sciences (SAVA) and Protagonist Therapeutics (PTGX).
View all of YMAB's competitors.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.15%) and DNB Asset Management AS (0.03%). Company insiders that own Y-mAbs Therapeutics stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics.

Which major investors are buying Y-mAbs Therapeutics stock?

YMAB stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and DNB Asset Management AS. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics or or view top insider-buying stocks.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $10.22.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics has a market capitalization of $446.04 million and generates $20.75 million in revenue each year. The company earns $-119.34 million in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

Y-mAbs Therapeutics employs 125 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

Where are Y-mAbs Therapeutics' headquarters?

Y-mAbs Therapeutics is headquartered at 230 Park Avenue Suite 3350, NEW YORK NY, 10169.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at (646) 885-8505 or via email at [email protected].